Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gevokizumab in Behçet's Disease Uveitis
NCT01965145Phase 3Terminated
- Sponsor
- Servier
- Start
- Nov 2012
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Behçet's disease (BD) comparing Gevokizumab with Placebo (2 arms). Primary endpoint: Time to first acute ocular exacerbation at 3 years. Started Nov 2012; status: terminated.
02
Drugs
gevokizumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT01965145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965145.